Showing 5221-5230 of 8126 results for "".
- ZELTIQ® Taps Todd Zavodnick as New President, Internationalhttps://practicaldermatology.com/news/zeltiq-taps-todd-zavodnick-as-new-president-international/2458708/Todd Zavodnick is the new President, International of ZELTIQ®. Mr. Zavodnick will be responsible for driving the company’s international growth and expansion. He rec
- Traffic-related Air pollution Linked to Facial Lentigeneshttps://practicaldermatology.com/news/traffic-related-air-pollution-linked-to-facial-lentigenes/2458707/High levels of traffic-related air pollution and air pollution-associated gases may increase risk of developing facial lentigenes, new research suggests. "While NO2 exposure is known to be associated with low lung function and lung cancer, the effect o
- ASDS: Cosmetic Treatments Can Correct Facial Deformities Toohttps://practicaldermatology.com/news/asds-cosmetic-treatments-can-correct-facial-deformities-too/2458714/Soft-tissue fillers, neurotoxins and lasers can be used to correct facial deformities caused by a variety of medical conditions, according to information presented at the 2015 American Society for Dermatologic Surgery meeting. During the session, Wa
- Take That, Zika! New Wearable Device Protects Against Mosquitoes that Transmit Zikahttps://practicaldermatology.com/news/take-that-zika-new-wearable-device-protects-against-mosquitoes-that-transmit-zika/2458722/OFF!® Clip-On™ repellent device may help keep Zika-carrying mosquitoes at bay, according to an article in the Journal of Medical Entomol
- Vyome Biosciences: FDA Has Accepted IND for Investigational Acne Therapyhttps://practicaldermatology.com/news/vyome-biosciences-fda-has-accepted-ind-for-investigational-acne-therapy/2458728/The FDA has accepted from Vyome Biosciences an Investigational New Drug (IND) Application for the initiation of clinical studies for its lead program VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon.<
- Novartis Teams with Pro Football Hall of Famer Troy Aikman on Melanoma Educationhttps://practicaldermatology.com/news/novartis-teams-with-pro-football-hall-of-famer-troy-aikman-on-melanoma-education/2458727/Troy Aikman, diagnosed with stage II melanoma in 1998, has teamed up with Novartis for the Melanoma Just Got Personal campaign. The campaign has created personalized markings to show the different mutations of melanoma. Campaign partners are asking patients and supporters to show th
- Study: Women Younger than 40 at Melanoma Diagnosis Indoor Tanned Earlier, Morehttps://practicaldermatology.com/news/study-women-younger-than-40-at-melanoma-diagnosis-indoor-tanned-earlier-more/2458731/Melanoma among younger individuals is on the rise, and now new research suggests that initiating indoor tanning at an earlier age and more frequent tanning may be to blame. In the study, women younger than 40 when diagnosed with melanoma reported initiating indoor tanning at an earlier ag
- New Web Tool May Curb Indoor Tanning Use Among Coedshttps://practicaldermatology.com/news/new-web-tool-may-curb-indoor-tanning-use-among-coeds/2458737/A web-based intervention that taps into indoor tanning users’ perceptions about the value of tanning may help curb tanning bed use among young females, suggests research out of Rutgers Cancer Institute of New Jersey in New Brunswick. Research has shown that some indoor tanners do so
- Study: MD Complete Holds Its Own Against Two Rx Skincare Regimenshttps://practicaldermatology.com/news/md-complete-holds-own-against-two-rx-skincare-regimens/2458736/A new split-face study suggests that a mass marketed skin care system can hold its own against two prescription skin care regimens when it comes to improving photoaged skin. The new findings, which compared MD Complete with two professi
- FDA Approves Two New indications for Cosentyxhttps://practicaldermatology.com/news/fda-approves-tow-new-indications-for-cosentyx/2458745/The FDA has approved Cosentyx® (secukinumab, Novartis) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both life-long, painful and debilitating inflammatory diseases tha